Articles related to Infectious Diseases

The Infectious Diseases Society of America (IDSA) has issued guidance on managing drug interactions with nirmatrelvir/ritonavir (Paxlovid). Specifically, the IDSA recommends clinicians take six steps to minimize the risk of drug interactions for patients with COVID-19 who are eligible for nirmatrelvir/ritonavir.

Although vaccinations to the arm can still prevent serious illness, their ability to ward off infection completely has been diminished. And part of the reason may be the location of the vaccines, which some scientists now want to change by delivering inoculations to the site where the virus first makes contact: the nose. Three separate nasal sprays, now in advanced trials, could trigger stronger immune responses in people who have COVID-19.

How does the diagnostic performance of home antigen tests change during the course of SARS-CoV-2 infection? Symptomatic individuals with an initial negative home antigen test result for SARS-CoV-2 infection should test again one to two days later because test sensitivity seems to peak several days after illness onset.

The Centers for Disease Control and Prevention (CDC) warns that the incidence of sexually transmitted diseases (STDs) in the US continued to rise during the first year of the pandemic. For the first time in seven years, the overall number of reported STD cases was lower than the previous year, but the CDC attributed the drop-off to a decline in reported cases of chlamydia — the nation’s most common STD — that was likely a result of pandemic-related interruptions to screening.

This quiz tests your knowledge on the appropriate screening follow-up from a 23-year-old woman who was treated for gonococcal arthritis. After a physical exam that showed a complete resolution of symptoms, which screening test is the next course of action? A CD4 lymphocyte subset? Serum IgA level? Total hemolytic complement (CH50) level? Is any additional testing even needed?

Although there now exist many safe and approved therapeutics for non-hospitalized patients who have COVID-19 or one of its variants, these therapies are often distributed in an ineffective and unequitable manner, according to an article published by JAMA Network. The article highlights many of the available therapies and how to distribute them fairly to patients when demand exceeds available supply.